Status:
COMPLETED
AV Node Isolation in Atrial Fibrillation vs. Modulation by "Pace and Ablate" Strategy
Lead Sponsor:
Heart and Diabetes Center North-Rhine Westfalia
Conditions:
Atrial Fibrillation
AV Node Ablation
Eligibility:
All Genders
18-100 years
Brief Summary
AV-node ablation (AVNA) is a common therapy option for rate control strategy of permanent atrial fibrillation with numerous side effects. The investigators hypothesised that an isolation of the AV nod...
Eligibility Criteria
Inclusion
- paroxysmal, persistend or permanent atrial fibrillation; indication for AVNA
Exclusion
- other indications for AVNA than atrial fibrillation as AVNRT, atrial flutter, atrial tachycardia
Key Trial Info
Start Date :
October 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 28 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04859933
Start Date
October 1 2020
End Date
February 28 2022
Last Update
August 9 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herz- und Diabeteszentrum NRW, Ruhr-Universität Bochum
Bad Oeynhausen, Germany, 32545